Current Markers and Their Value in the Era of Immuno-oncology

Overview

Journal Transl Androl Urol

Date 2018 Jan 23

PMID 29354497

Citations 5

Authors

Friedrich-Carl von Rundstedt

Andrea Necchi

Affiliations

Soon will be listed here.

Abstract

Immunotherapy in urothelial cancer is a quickly evolving field as new agents are being investigated in multiple clinical trials and various clinical settings. The purpose of this review is to provide an insight into the mechanism of these treatments, potential targets to evaluate treatment response and to give an update on the current status of clinical trials. Urothelial cancer is a polyclonal disease with a substantial tumor heterogeneity and a high mutational load which may be beneficial as this may trigger a stronger T-cell mediated immune response. PD-1 expression has been shown to correlate with stage, grade, progression and poorer survival but it appears challenging to be utilized as a predictor for treatment response in urothelial cancer. Another important concept is immune cell (IC) infiltration, which is a reflection of the activated immune response within the target tissue. Marker genes may represent signaling pathways involved in T-cell recognition and lysis of T-cells. The complexity of the tumor and host interaction requires multiple concepts to be integrated into a future model to assess treatment response. We have evaluated multiple biomarker approaches currently investigated in clinical trials in urothelial cancer.

Citing Articles

Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment.

Hafez Ghoran S, Calcaterra A, Abbasi M, Taktaz F, Nieselt K, Babaei E Molecules. 2022; 27(16).

PMID: 36014474 PMC: 9414608. DOI: 10.3390/molecules27165236.

Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer.

Han Z, Mo R, Cai S, Feng Y, Tang Z, Ye J Front Cell Dev Biol. 2022; 10:831329.

PMID: 35531101 PMC: 9068940. DOI: 10.3389/fcell.2022.831329.

Long-term response of metastatic renal clear cell carcinoma following a subcutaneous injection of mixed bacterial vaccine: a case report.

Chen J, Lv Y, Mu F, Xu K Onco Targets Ther. 2019; 12:2531-2538.

PMID: 31040696 PMC: 6454994. DOI: 10.2147/OTT.S200414.

The clinical applications of The Cancer Genome Atlas project for bladder cancer.

Creighton C Expert Rev Anticancer Ther. 2018; 18(10):973-980.

PMID: 30081681 PMC: 6295312. DOI: 10.1080/14737140.2018.1508999.

Current status and future directions of cancer immunotherapy.

Zhang H, Chen J J Cancer. 2018; 9(10):1773-1781.

PMID: 29805703 PMC: 5968765. DOI: 10.7150/jca.24577.

References

Ilie M, Hofman V, Dietel M, Soria J, Hofman P . Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016; 468(5):511-25. DOI: 10.1007/s00428-016-1910-4. View

Powles T, ODonnell P, Massard C, Arkenau H, Friedlander T, Hoimes C . Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017; 3(9):e172411. PMC: 5824288. DOI: 10.1001/jamaoncol.2017.2411. View

Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 389(10064):67-76. PMC: 5568632. DOI: 10.1016/S0140-6736(16)32455-2. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Chen P, Roh W, Reuben A, Cooper Z, Spencer C, Prieto P . Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016; 6(8):827-37. PMC: 5082984. DOI: 10.1158/2159-8290.CD-15-1545. View

Xylinas E, Robinson B, Kluth L, Volkmer B, Hautmann R, Kufer R . Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2013; 40(1):121-7. DOI: 10.1016/j.ejso.2013.08.023. View

Inman B, Sebo T, Frigola X, Dong H, Bergstralh E, Frank I . PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007; 109(8):1499-505. DOI: 10.1002/cncr.22588. View

Mansfield A, Aubry M, Moser J, Harrington S, Dronca R, Park S . Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016; 27(10):1953-8. PMC: 5035793. DOI: 10.1093/annonc/mdw289. View

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

10.

Patel S, Sanjana N, Kishton R, Eidizadeh A, Vodnala S, Cam M . Identification of essential genes for cancer immunotherapy. Nature. 2017; 548(7669):537-542. PMC: 5870757. DOI: 10.1038/nature23477. View

11.

. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View

12.

McCarthy E . The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006; 26:154-8. PMC: 1888599. View

13.

Boorjian S, Sheinin Y, Crispen P, Farmer S, Lohse C, Kuntz S . T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008; 14(15):4800-8. DOI: 10.1158/1078-0432.CCR-08-0731. View

14.

Zibelman M, Ramamurthy C, Plimack E . Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. Urol Oncol. 2016; 34(12):538-547. DOI: 10.1016/j.urolonc.2016.10.017. View

15.

Galon J, Pages F, Marincola F, Angell H, Thurin M, Lugli A . Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10:205. PMC: 3554496. DOI: 10.1186/1479-5876-10-205. View

16.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

17.

Patel M, Ellerton J, Infante J, Agrawal M, Gordon M, Aljumaily R . Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2017; 19(1):51-64. PMC: 7984727. DOI: 10.1016/S1470-2045(17)30900-2. View

18.

Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A . Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015; 10(6):e0130142. PMC: 4472786. DOI: 10.1371/journal.pone.0130142. View

19.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

20.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View